Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity-Reference-Cited by-同舟云学术

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

Published:2011-04 Issue:1-2 Volume:303 Page:50-52
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Siger Małgorzata,Durko Agnieszka,Nicpan Agnieszka,Konarska Maria,Grudziecka Monika,Selmaj Krzysztof

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference13 articles.

1. Treatment optimization in multiple sclerosis: report of an international consensus meeting;International Working Group for Treatment Optimization in MS;Eur J Neurol,2004

2. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized-double-blind, placebo-controlled trial;The IFNB Multiple Sclerosis Study Group;Neurology,1993

3. Intramuscular interferon ß-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann Neurol,1996

4. Randomized double-blind placebo controlled study of interferon ß-1a in relapsing–remitting multiple sclerosis;PRISM Study Group;Lancet,1998

5. Defining the response to interferon-ß in relapsing–remitting multiple sclerosis;Rio;Ann Neurol,2006

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

2. Multiple sclerosis relapse presenting as trigeminal neuralgia;Radiology Case Reports;2024-08

3. Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies;CNS Drugs;2023-09-23

4. Iranian specialists’ approach to surgery in patients with multiple sclerosis;Current Journal of Neurology;2023-08-08

5. Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM;Neurological Research;2022-10-02